You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Administration of cultured autologous bone marrow stromal cells into cerebrospinal fluid in spinal injury patients: A pilot study

Article type: Research Article

Authors: Saito, Fukuki | Nakatani, Toshio | Iwase, Masaaki | Maeda, Yuji | Murao, Yoshinori | Suzuki, Yoshihisa | Fukushima, Masanori | Ide, Chizuka

Affiliations: Emergency and Critical Care Center, Kansai Medical University, Moriguchi, Osaka, Japan | Department of Plastic and Reconstructive Surgery, Kitano Hospital, Tazuke Kofukai Medical Research Institute, Osaka, Japan | Translational Research Informatics Center, Kobe, Japan | Institute of Regeneration and Rehabilitation, Faculty of Nursing and Rehabilitation, Aino University, Osaka, Japan

Note: [] Corresponding author: Toshio Nakatani, MD, Department of Emergency and Critical Care Medicine, Kansai Medical University, 10–15, Fumizono-cho, Moriguchi, 570-8507 Osaka, Japan. Tel.:/Fax: +81 6 6993 9530; E-mail: [email protected]

Keywords: Spinal cord injury treatment, bone marrow stromal cell, spinal cord regeneration, cerebrospinal fluid

DOI: 10.3233/RNN-2011-0629

Journal: Restorative Neurology and Neuroscience, vol. 30, no. 2, pp. 127-136, 2012

Published: 2012
Get PDF open access

Abstract

Purpose: To determine whether intrathecal administration of cultured autologous bone marrow stromal cells (BMSCs) is safe and feasible for treatment of subacute spinal injury. Methods: Five patients with complete tetraplegia due to cervical spinal injury on admission were included. A small amount of bone marrow was obtained during surgery for spinal fusion. BMSCs were cultured, reaching 107–108 cells. The properties and functional efficacy of the BMSCs were verified with surface marker analysis and a neurite extension test. BMSCs were administered by lumbar puncture. The patients were closely observed for 6 months, and the Committee on Effectiveness and Safety of Clinical Treatment (CESCT) evaluated safety. Results: No adverse responses were observed in biochemical and radiographic examinations. The CESCT did not recognize any harmful effects of the transplantation, and concluded it was safe for treatment. The patients were further followed up for 1 to 4 years with no adverse responses. The recovery of American Spinal Injury Association Impairment Scale (AIS) B and C patients at transplantation was rapid and remarkable, but gradual or limited in AIS A patients. Conclusion: This study demonstrated that intrathecal administration of cultured autologous BMSCs is safe and feasible for treatment of spinal cord injury.

Show more